HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term application of glycine transporter inhibitors acts antineuropathic and modulates spinal N-methyl-D-aspartate receptor subunit NR-1 expression in rats.

AbstractBACKGROUND:
Dysfunction of spinal glycinergic neurotransmission is a major pathogenetic factor in neuropathic pain. The synaptic glycine concentration is controlled by the two glycine transporters (GlyT) 1 and 2. GlyT inhibitors act antinociceptive in various animal pain models when applied as bolus. Yet, in some studies, severe neuromotor side effects were reported. The aim of the current study was to elucidate whether continuous inhibition of GlyT ameliorates neuropathic pain without side effects and whether protein expression of GlyT1, GlyT2, or N-methyl-D-aspartate receptor subunit NR-1 in the spinal cord is affected.
METHODS:
In the chronic constriction injury model of neuropathic pain, male Wistar rats received specific GlyT1 and GlyT2 inhibitors (ALX5407 and ALX1393; Sigma-Aldrich, St. Louis, MO) or vehicle for 14 days via subcutaneous osmotic infusion pumps (n = 6). Mechanical allodynia and thermal hyperalgesia were assessed before, after chronic constriction injury, and every 2 days during substance application. At the end of behavioral assessment, the expression of GlyT1, GlyT2, and NR-1 in the spinal cord was determined by Western blot analysis.
RESULTS:
Both ALX5407 and ALX1393 ameliorated thermal hyperalgesia and mechanical allodynia in a time- and dose-dependent manner. Respiratory or neuromotor side effects were not observed. NR-1 expression in the ipsilateral spinal cord was significantly reduced by ALX5407, but not by ALX1393. The expression of GlyT1 and GlyT2 remained unchanged.
CONCLUSIONS:
Continuous systemic inhibition of GlyT significantly ameliorates neuropathic pain in rats. Thus, GlyT represent promising targets in pain research. Modulation of N-methyl-D-aspartate receptor expression might represent a novel mechanism for the antinociceptive action of GyT1 inhibitors.
AuthorsFranziska Barthel, Andrea Urban, Lukas Schlösser, Volker Eulenburg, Robert Werdehausen, Timo Brandenburger, Carmen Aragon, Inge Bauer, Henning Hermanns
JournalAnesthesiology (Anesthesiology) Vol. 121 Issue 1 Pg. 160-9 (Jul 2014) ISSN: 1528-1175 [Electronic] United States
PMID24598217 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • (R)-(N-(3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl))sarcosine
  • ALX 1393
  • Glycine Plasma Membrane Transport Proteins
  • NR1 NMDA receptor
  • Receptors, N-Methyl-D-Aspartate
  • Serine
  • Sarcosine
Topics
  • Animals
  • Behavior, Animal (drug effects)
  • Blotting, Western
  • Constriction, Pathologic (drug therapy, pathology)
  • Dose-Response Relationship, Drug
  • Glycine Plasma Membrane Transport Proteins (antagonists & inhibitors)
  • Hyperalgesia (drug therapy, pathology)
  • Male
  • Neuralgia (drug therapy, psychology)
  • Pain Measurement (drug effects)
  • Rats
  • Rats, Wistar
  • Receptors, N-Methyl-D-Aspartate (biosynthesis)
  • Sarcosine (adverse effects, analogs & derivatives, pharmacology)
  • Serine (adverse effects, analogs & derivatives, pharmacology)
  • Spinal Cord (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: